We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Value Investors Consider Amdocs (DOX) Stock Now?
Read MoreHide Full Article
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Amdocs Limited (DOX - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Amdocs has a trailing twelve months PE ratio of 12.39, as you can see in the chart below:
This level also compares favorably with the market at large, as the PE for the S&P 500 stands at about 14.88. Meanwhile, if we focus on the long-term PE trend, Amdocs’ current PE level puts it below its midpoint of 17.81 over the past five years.
The stock’s PE also compares quite favorably with the Computer and Technology Market’s trailing twelve months PE ratio, which stands at 19.47. This indicates that the stock is undervalued right now, compared to its peers.
We should also point out Amdocs has a forward PE ratio (price relative to this year’s earnings) of 11.34, so it is fair to say that a more value-oriented path is ahead of the stock in the near term.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Amdocs has a P/S ratio of 1.71. This is much lower than the S&P 500 average, which comes in at 2.59 right now. Also, as we can see in the chart below, this is somewhat below the highs for this stock in particular over the past few years.
Broad Value Outlook
In aggregate, Amdocs currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Amdocs a solid choice for value investors and some of its other key metrics make this pretty clear too.
For example, the P/CF ratio comes in at 8.92, which is somewhat better than the industry average of 10.63. Clearly, DOX is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Amdocs might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and a Momentum Score of D. This gives DOX a Zacks VGM score — or its overarching fundamental grade — of C. (You can read more about the Zacks Style Scores here >>).
Meanwhile, the company’s recent earnings estimates have been somewhat downbeat. While the current-quarter estimate has seen no upward and four downward movements, the current-year estimate has seen one upward and two downward movements over the past two months.
This has had a negative effect on the consensus estimate. While the current-quarter consensus has dropped 3.6% over the past two months, the current-year estimate declined 0.9%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Despite this somewhat bearish trend, the stock has a Zacks Rank #3 (Hold) and it is the reason why we are looking for inline performance from the company in the near term.
Bottom Line
Amdocs is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Despite a strong industry rank (among top 40% of more than 250 industries), with a Zacks Rank #3 it is hard to get too excited about the stock.
Also, over the past two years, the broader industry has clearly underperformed the market at large, as you can see below:
Hence, value investors might want to wait for Zacks Rank, past industry performance, and analyst sentiments to turn around in the name first, but once that happens, the stock is going to be a compelling pick.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Should Value Investors Consider Amdocs (DOX) Stock Now?
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Amdocs Limited (DOX - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Amdocs has a trailing twelve months PE ratio of 12.39, as you can see in the chart below:
This level also compares favorably with the market at large, as the PE for the S&P 500 stands at about 14.88. Meanwhile, if we focus on the long-term PE trend, Amdocs’ current PE level puts it below its midpoint of 17.81 over the past five years.
The stock’s PE also compares quite favorably with the Computer and Technology Market’s trailing twelve months PE ratio, which stands at 19.47. This indicates that the stock is undervalued right now, compared to its peers.
We should also point out Amdocs has a forward PE ratio (price relative to this year’s earnings) of 11.34, so it is fair to say that a more value-oriented path is ahead of the stock in the near term.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Amdocs has a P/S ratio of 1.71. This is much lower than the S&P 500 average, which comes in at 2.59 right now. Also, as we can see in the chart below, this is somewhat below the highs for this stock in particular over the past few years.
Broad Value Outlook
In aggregate, Amdocs currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Amdocs a solid choice for value investors and some of its other key metrics make this pretty clear too.
For example, the P/CF ratio comes in at 8.92, which is somewhat better than the industry average of 10.63. Clearly, DOX is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Amdocs might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and a Momentum Score of D. This gives DOX a Zacks VGM score — or its overarching fundamental grade — of C. (You can read more about the Zacks Style Scores here >>).
Meanwhile, the company’s recent earnings estimates have been somewhat downbeat. While the current-quarter estimate has seen no upward and four downward movements, the current-year estimate has seen one upward and two downward movements over the past two months.
This has had a negative effect on the consensus estimate. While the current-quarter consensus has dropped 3.6% over the past two months, the current-year estimate declined 0.9%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Amdocs Limited Price and Consensus
Amdocs Limited price-consensus-chart | Amdocs Limited Quote
Despite this somewhat bearish trend, the stock has a Zacks Rank #3 (Hold) and it is the reason why we are looking for inline performance from the company in the near term.
Bottom Line
Amdocs is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Despite a strong industry rank (among top 40% of more than 250 industries), with a Zacks Rank #3 it is hard to get too excited about the stock.
Also, over the past two years, the broader industry has clearly underperformed the market at large, as you can see below:
Hence, value investors might want to wait for Zacks Rank, past industry performance, and analyst sentiments to turn around in the name first, but once that happens, the stock is going to be a compelling pick.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>